Consumers depend on more than a shipment reaching a digital queue. In its November 29, 2016 import-data rule, the Food and Drug Administration clarified that it could reject a filing lacking complete and accurate required information. The provision connects border paperwork to the agency's decision about whether an FDA-regulated product may enter the United States. [2016-28582]

The agency allowed one limited accommodation: an importer could submit UNK for the intended-use code at entry. That did not excuse the other applicable information or guarantee release. FDA explained that this choice would usually bring manual review. For people awaiting products, a successfully transmitted record and a completed admissibility decision therefore meant different things. [2016-28582]

The July 1 proposal supplies an important boundary. It said the proposed electronic-filing requirements would not affect the ability to submit paper entries and entry summaries. That was a statement about the proposal's scope, not evidence that every later filing qualified for a paper exemption. The two documents describe stages of the same FDA process, rather than independent assessments of border performance. [2016-15684][2016-28582]

The final rule specified December 29 effectiveness; FDA said ACE had already become the sole authorized electronic system on July 23. Its stated public-health aim was to concentrate limited resources on riskier products. Complete information was the mechanism, not proof that harm had already fallen. The consumer question remains whether better records translate into better decisions without avoidable delays. [2016-28582]

Source documents

  1. Submission of Food and Drug Administration Import Data in the Automated Commercial Environmenthttps://www.govinfo.gov/content/pkg/FR-2016-11-29/html/2016-28582.htm
  2. Submission of Food and Drug Administration Import Data in the Automated Commercial Environmenthttps://www.govinfo.gov/content/pkg/FR-2016-07-01/html/2016-15684.htm